Pertuzumab + trastuzumab + Pertuzumab + trastuzumab + metronomic chemotherapy
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Elderly Metastatic Breast Cancer Population
Conditions
Elderly Metastatic Breast Cancer Population
Trial Timeline
Jun 1, 2013 → Nov 1, 2022
NCT ID
NCT01597414About Pertuzumab + trastuzumab + Pertuzumab + trastuzumab + metronomic chemotherapy
Pertuzumab + trastuzumab + Pertuzumab + trastuzumab + metronomic chemotherapy is a phase 2 stage product being developed by Roche for Elderly Metastatic Breast Cancer Population. The current trial status is completed. This product is registered under clinical trial identifier NCT01597414. Target conditions include Elderly Metastatic Breast Cancer Population.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01597414 | Phase 2 | Completed |
Competing Products
15 competing products in Elderly Metastatic Breast Cancer Population
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YM150 + Placebo | Astellas Pharma | Phase 1 | 33 |
| ASP3325 + Placebo | Astellas Pharma | Phase 1 | 33 |
| E2022 Tape Formulation | Eisai | Phase 1 | 33 |
| Donepezil | Eisai | Approved | 85 |
| AZD3293 + Placebo | AstraZeneca | Phase 1 | 33 |
| TC-5214 + Placebo | AstraZeneca | Phase 1 | 33 |
| AZD3293 + Placebo | AstraZeneca | Phase 1 | 33 |
| Esmirtazapine | Merck | Phase 3 | 77 |
| PF-06648671 + Midazolam + Placebo | Pfizer | Phase 1 | 32 |
| PF-06743649 + Placebo + PF-06743649 + Placebo + PF-06743649 + Placebo + PF-06743649 + Placebo + PF-06743649 + Placebo | Pfizer | Phase 1 | 32 |
| Vitamin D + Sham Exercise + Vitamin D + Exercise | Pfizer | Phase 1 | 32 |
| HSK3486 + HSK3486 + HSK3486 + HSK3486 | Haisco Pharmaceutical Group | Phase 1 | 30 |
| Padsevonil | UCB | Phase 1 | 30 |
| TD-1439 + Placebo | Theravance Biopharma | Phase 1 | 28 |
| TD-0714 + Placebo | Theravance Biopharma | Phase 1 | 28 |